Liver News and Research

RSS

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

Flu shots may reduce risk of blood clots forming in veins

Flu shots may reduce the risk of blood clots forming in veins by 26 percent, according to research presented at the American Heart Association's Scientific Sessions 2008.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Researchers screen 700 molecules by RNAi to identify host factors involved in malaria infection

The researchers of the Malaria Unit at Instituto de Medicina Molecular (IMM, Lisbon, Portugal) publish in the peer reviewed journal PLoS Pathogens the results of a large scale screening of more than 700 genes to identify host factors involved in the liver stage of malaria infection.

7 Nov 2008

Fat tissue found to produce melanin

A two-year study conducted by researchers at George Mason University, INOVA Fairfax Hospital and the National Cancer Institute may open the door to new therapies for combating chronic diseases associated with obesity, a condition that affected more than 33 percent of American adults in 2005-06 according to the Centers for Disease Control and Prevention.

7 Nov 2008

Caesarean sections do not reduce hepatitis C transmission

Planned Caesarean sections do not help to reduce the chances of a pregnant mother with Hepatitis C (HCV) transmitting the infection to her unborn baby, according to new scientific findings by the National Maternity Hospital in Dublin and University College Dublin.

7 Nov 2008

Solutions to inequities in kidney transplant allocation

Depending on where they live in the United States, patients needing a kidney transplant can wait just one year for a deceased donor's kidney or up to 10 years.

7 Nov 2008

Age is not an independent factor in cancer survival rates, but clinical trials exclude older patients

Age is not an independent factor in cancer survival rates and should not influence decisions about how to treat older patients, according to a study in the November issue of IJCP, the Independent Journal of Clinical Practice.

7 Nov 2008

Scientists confirm a molecular clipping mechanism behind stem cell development

Stem cells don't just become a part of the liver or the brain in a flash; it takes a complex molecular choreography and requires that specific genes be switched on and off at specific times.

6 Nov 2008

10 symptoms that should never be ignored

Not every ache and pain merits a quick trip to the doctor -- but some do.

6 Nov 2008

Lung airway cells activate vitamin D and increase immune response

Vitamin D is essential to good health but needs to be activated to function properly in the human body.

5 Nov 2008

New weapon in the fight against obesity and diabetes

A study appearing November 5 in the journal Cell Metabolism demonstrates that a synthetic new chemical entity protects against diet-induced obesity, improves glucose tolerance and insulin sensitivity and enhances exercise endurance by enhancing fat utilization in certain target tissues.

4 Nov 2008

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

4 Nov 2008

Liver transplant recipients face increased risks of developing cancer

A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer.

4 Nov 2008

Important steps towards the development of a human vaccine against malaria

Every day 2,000 children die from malaria in Africa alone. The infection is transmitted from human to human by biting mosquitoes and remains one of the world's most devastating diseases. Despite many years of effort a vaccine is still not available but is urgently needed, if we are to make an impact on this enormous problem.

31 Oct 2008

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

31 Oct 2008

Earlier jaundice treatment decreases brain injury in preterm infants

A study from a National Institutes of Health research network found that an early treatment to prevent severe newborn jaundice in extremely early preterm infants reduced the infants' rate of brain injury, a serious complication of severe jaundice.

30 Oct 2008

By imaging live cells, researchers show how hepatitis C replicates

The hepatitis C virus is a prolific replicator, able to produce up to a trillion particles per day in an infected person by hijacking liver cells in which to build up its viral replication machinery.

30 Oct 2008

Researchers discover new way to attack some forms of leukemia

Each year, some 29,000 adults and 2,000 children are diagnosed with leukemia, a form of cancer that is caused by the abnormal production of white blood cells in the bone marrow. Current treatments rely primarily on killing the cancer cells, which also destroys normal cells. But what if a way could be found to reprogram cancerous cells back into normal cells? A team of Syracuse University researchers believes it may have found a way to do just that.

28 Oct 2008

Phenomix starts phase 1a trial of hepatitis C protease inhibitor

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

28 Oct 2008